Co-absence of TP53 and LNK genes have been shown to initiate pre-B ALL that resembles Ph-like B-ALL with JAK/STAT/mTOR pathway activation and responds in vitro and in vivo to JAK inhibitor (Ruxolitinib) and the dual mTOR and PI3K inhibitor (BEZ235) [85]. The gene discussed is SH2B3; the disease is acute lymphoblastic leukemia.